Philips Enhances Neurological Diagnosis with the Launch of IntelliSpace Portal 9.0

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) has announced the introduction of IntelliSpace Portal 9.0, the latest edition of its comprehensive, advanced visual analysis and quantification platform. Featuring a suite of multi-modality functions and expanded neurological tools, IntelliSpace Portal 9.0 helps radiologists detect, diagnose and follow-up on treatment of diseases, while using new machine learning capabilities to support the physician. The solution addresses radiologists' needs for tools to better support the growing group of patients with brain injuries and neurological disorders such as dementia, strokes, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

In addition to enhancements in areas such as CT Brain Perfusion and MR T2 Perfusion IntelliSpace Portal 9.0 will offer Longitudinal Brain Imaging (LoBI) , an application for neuro reading to support the evaluation of neurological disorders over time so clinicians can monitor disease progression. Another feature is the inclusion of the NeuroQuant® measurement application (CorTech Labs, Inc.) which enables clinicians to quantify brain volume loss.

"As the rates of dementia and neurodegeneration rise, neuroradiologists need advanced tools to help referring physicians treat these challenging cases," said Professor Dr. Leo Wolansky, Acting Chief of Neuroradiology at University Hospitals Cleveland Medical Center in the United States. "IntelliSpace Portal 9.0 offers a comprehensive set of robust tools so neuroradiologists can quantify disease expediently."

With more than 70 applications and enhancements of many of the core applications, IntelliSpace Portal 9.0 is a single platform for visual analysis and quantification that spans clinical domains within radiology, including neurology, oncology, and cardiology. The platform offers improved advanced 3D rendering and refined STL export that enable clinicians to print 3D models with high-levels of detail and resolution, to help understand the anatomy. IntelliSpace Portal 9.0 also includes enhancements to a host of core applications from MR Cardiac Analysis to CT TAVI planning, and System enhancements.

"Radiology has a unique ability to influence and improve outcomes, and intelligent tools enable us to empower radiologists with the right information," said Yair Briman, Senior Vice President and General Manager of Healthcare IT for Philips. "With advances in machine learning, IntelliSpace Portal 9.0 will now be able to continually learn the usage patterns of users to enhance the important daily functions of a radiologist such as pre-preprocessing of images, encouraging faster and more streamlined diagnosis."

IntelliSpace Portal 9.0 offers multimodality clinical applications that can be accessed from any point of the hospital network. The solution can also integrate with typical PACS and hospital information systems to allow for information to be shared broadly, helping drive collaboration across the network. With the enterprise scalability of IntelliSpace Portal 9.0, neurologists can access the power of advanced analysis virtually anywhere across their organization while maintaining consistent applications and user preferences. Some additional highlights of Version 9.0 of the Portal include:

  • MR Cardiac Enhancements - Facilitates easy visual scoring in various examination contexts. The package enables comprehensive functional volumetric analysis. Enhancements to the package include Whole Heart STL export for 3D printing, and enhanced workflow and batch tools.
  • CT Spectral Applications - Philips IntelliSpace Portal Spectral Diagnostic suite of clinical applications has been optimized for the viewing and analysis of spectral data sets from the IQon Spectral CT scanner. You can access the application you need when and where you need, virtually anywhere in your enterprise. The tools help you gain a comprehensive overview of each patient, quantify quickly, and diagnose with confidence.

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 70,000 employees with sales and services in more than 100 countries.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...